Insider Selling: Cryoport, Inc. (NASDAQ:CYRX) CEO Sells 4,620 Shares of Stock

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 4,620 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. The trade was a 0.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The stock was sold at an average price of $4.88, for a total value of $20,364.24.

Cryoport Stock Down 1.2 %

CYRX stock opened at $5.77 on Friday. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The firm has a 50 day simple moving average of $6.86 and a 200-day simple moving average of $7.41. The company has a market capitalization of $287.98 million, a P/E ratio of -1.71 and a beta of 1.67. Cryoport, Inc. has a twelve month low of $4.58 and a twelve month high of $20.11.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The company had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter last year, the firm posted ($0.29) EPS. On average, equities research analysts predict that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CYRX. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Cryoport in a research report on Wednesday, March 5th. Guggenheim started coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Institutional Trading of Cryoport

Several institutional investors and hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. raised its stake in Cryoport by 0.4% during the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock valued at $3,012,000 after buying an additional 1,512 shares in the last quarter. Rhumbline Advisers raised its position in shares of Cryoport by 2.9% during the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after acquiring an additional 1,764 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Cryoport by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after acquiring an additional 2,120 shares in the last quarter. Nebula Research & Development LLC raised its holdings in shares of Cryoport by 21.6% during the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock worth $97,000 after purchasing an additional 2,207 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Cryoport by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after purchasing an additional 2,226 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.